false 0001645469 0001645469 2024-08-27 2024-08-27
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 27, 2024
 
MONOPAR THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-39070
  
32-0463781
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)
 
1000 Skokie Blvd., Suite 350, Wilmette, IL
  
60091
(Address of principal executive offices)
  
(Zip Code)
 
(847) 388-0349
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.001 par value
  
MNPR
  
The Nasdaq Stock Market LLC (Nasdaq Capital Market)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
 
 
 
 
 
Item 7.01  Regulation FD Disclosure. 
 
On August 27, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that Monopar regained compliance with Nasdaq's minimum bid price rule.
 
The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits
 
Exhibit No.  
  
Description
 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Monopar Therapeutics Inc.
  
       
Date: August 27, 2024
By:
/s/ Karthik Radhakrishnan
  
 
Name:
Karthik Radhakrishnan
  
 
Title:
Chief Financial Officer
  
 
 

Exhibit 99.1

 

monologo.jpg

 

 

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

 

WILMETTE, Ill., August 27, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing.

 

About Monopar Therapeutics Inc. 

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com

 

CONTACT:  

 

Monopar Therapeutics Inc.
Investor Relations  
Karthik Radhakrishnan  
Chief Financial Officer  
karthik@monopartx.com  

 

Follow Monopar on social media for updates: 

 

Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

 
v3.24.2.u1
Document And Entity Information
Aug. 27, 2024
Document Information [Line Items]  
Entity, Registrant Name MONOPAR THERAPEUTICS INC.
Document, Type 8-K
Document, Period End Date Aug. 27, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39070
Entity, Tax Identification Number 32-0463781
Entity, Address, Address Line One 1000 Skokie Blvd.
Entity, Address, Address Line Two Suite 350
Entity, Address, City or Town Wilmette
Entity, Address, State or Province IL
Entity, Address, Postal Zip Code 60091
City Area Code 847
Local Phone Number 388-0349
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol MNPR
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company true
Entity, Ex Transition Period true
Amendment Flag false
Entity, Central Index Key 0001645469
Monopar Therapeutics (NASDAQ:MNPR)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024 Haga Click aquí para más Gráficas Monopar Therapeutics.
Monopar Therapeutics (NASDAQ:MNPR)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024 Haga Click aquí para más Gráficas Monopar Therapeutics.